RB1 and central nervous system cancer: Another ongoing study is investigating single-agent Ribociclib in the adult population as a phase 0/2 non-randomized open-label trial evaluating preoperative dosing of oral Ribociclib in patients with Rb+ or non-Rb-mutated recurrent WHO Grade 2/3 meningioma or high-grade glioma (NCT02933736).